Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2011

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Report on Form 6-K is filed, and the Company does not intend to update any of the forward-looking statements after the date this Report on Form 6-K is filed to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC; changing legislation or regulatory environments in the PRC; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

This report is hereby incorporated by reference to the Registration Statement on Form F-3 (File No. 333-168873) of the Company.

Results of Operations and Financial Condition

Following this cover page are the preliminary unaudited consolidated financial results for the three months and six months ended September 30, 2011 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and September 30, 2011

	March 31,		September 30,
	2011		2011
	RMB		RMB		US$
	(in thousands except share data)

ASSETS
Current assets
Cash and cash equivalents		611,387		635,698		99,670
Accounts receivable, less allowance for doubtful accounts
(March 31, 2011: RMB11,850; September 30, 2011: RMB12,097)		77,402		81,144		12,722
Inventories		6,729		10,879		1,706
Prepaid expenses and other receivables		9,982		12,274		1,925
Trading securities		-		332		52
Amounts due from related parties		-		360		56
Income tax recoverable		-		3,979		624
Deferred tax assets		5,373		4,786		750
Total current assets		710,873		749,452		117,505
Property, plant and equipment, net		250,348		243,316		38,149
Non-current prepayments		5,752		8,649		1,356
Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2011: RMB28,106; September 30, 2011: RMB31,903)		240,952		253,689		39,776
Inventories		31,600		32,808		5,144
Intangible assets, net		134,412		132,102		20,712
Available-for-sale equity securities		52,733		10,681		1,675
Other investments		134,363		164,047		25,721
Deferred tax assets		2,565		3,438		539
Total assets		1,563,598		1,598,182		250,577

LIABILITIES
Current liabilities
Bank loan		45,000		45,000		7,056
Accounts payable		5,046		8,646		1,356
Accrued expenses and other payables		106,731		31,722		4,973
Deferred revenue		82,319		87,152		13,664
Amounts due to related parties		360		-		-
Income tax payable		11,156		8,719		1,367
Total current liabilities		250,612		181,239		28,416
Deferred revenue		162,668		233,872		36,669
Other non-current liabilities		30,036		44,337		6,952
Deferred tax liabilities		26,890		25,672		4,025
Total liabilities		470,206		485,120		76,062

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and September 30, 2011 – (continued)

	March 31,			September 30,
	2011			2011
	RMB			RMB		US$
	(in thousands except share data)

EQUITY
Shareholders’ equity
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 75,406,875 shares
and 73,638,115 shares issued and outstanding as of March 31, 2011 and
September 30, 2011, respectively		52			50		8
Additional paid-in capital		910,316			873,535		136,961
Accumulated other comprehensive loss		(18,580	)		(31,003)		(4,861)
Retained earnings		178,993			242,264		37,983
Total shareholders’ equity		1,070,781			1,084,846		170,091
Noncontrolling interests		22,611			28,216		4,424
Total equity		1,093,392			1,113,062		174,515
Total liabilities and equity		1,563,598			1,598,182		250,577

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Six Months Ended September 30, 2010 and 2011

	Three months ended September 30,							Six months ended September 30,
	2010			2011				2010			2011
	RMB			RMB		US$		RMB			RMB		US$
	(in thousands except per share)

Revenues		82,682			98,433		15,433		154,378			185,891		29,145
Direct costs		(19,154	)		(21,757)		(3,411)		(36,406	)		(41,625)		(6,526)
Gross profit		63,528			76,676		12,022		117,972			144,266		22,619
Operating expenses
Research and development		(1,794	)		(1,932)		(303)		(3,337	)		(3,709)		(582)
Sales and marketing		(11,684	)		(15,575)		(2,442)		(21,774	)		(28,181)		(4,418)
General and administrative		(20,856	)		(21,444)		(3,362)		(40,312	)		(43,899)		(6,884)
Total operating expenses		(34,334	)		(38,951)		(6,107)		(65,423	)		(75,789)		(11,884)
Operating income		29,194			37,725		5,915		52,549			68,477		10,735
Other income/(expense), net
Interest income		1,587			3,312		519		4,038			6,451		1,011
Interest expense		(672	)		(1,190)		(187)		(1,278	)		(1,650)		(259)
Exchange gain/(loss)		827			(4,956)		(777)		590			(4,860)		(762)
Dividend income		-			-		-		-			7,217		1,132
Others		774			111		17		890			325		51
Total other income/(expense), net		2,516			(2,723)		(428)		4,240			7,483		1,173
Income before income tax		31,710			35,002		5,487		56,789			75,960		11,908
Income tax expense		(8,112	)		(9,093)		(1,426)		(14,222	)		(7,310)		(1,146)
Net income		23,598			25,909		4,061		42,567			68,650		10,762
Income attributable to noncontrolling
interests		(1,616	)		(2,660)		(417)		(2,998	)		(5,379)		(843)
Net income attributable to
shareholders		21,982			23,249		3,644		39,569			63,271		9,919

Net income per share:
Attributable to ordinary shares
-Basic		0.33			0.31		0.05		0.59			0.85		0.13
-Diluted		0.33			0.31		0.05		0.58			0.85		0.13

Other Events

On November 28, 2011, the Company issued a press release announcing preliminary unaudited consolidated financial results for the three months and six months ended September 30, 2011. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.

Description

99.1

Press Release, dated November 28, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION

	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer

Dated: November 28, 2011